Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring Platelet function tests, Erythropoietin, Myocardial infarction
Eligibility Criteria
Inclusion Criteria: Age 21-75 years Clinical evidence of acute myocardial infarction (MI) with total or sub-total occlusion on angiogram Status post percutaneous revascularization procedure for acute MI with TIMI 3 flow Ongoing clinically-indicated treatment with aspirin, thienopyridines Exclusion Criteria: Hemodynamic instability/shock or severe congestive heart failure Time from onset of chest pain to revascularization procedure > 16 hours Use of intravenous thrombolytic agents for treatment of MI Known need for additional revascularization procedures
Sites / Locations
- Yale University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
A
B
recombinant human erythropoietin 200 U/kg IV daily for 3 days
Normal saline volume to match active treatment IV daily for 3 days